Zoetis Inc. Reports Revenue Increase to $2.4 Billion in Q3 2025

Zoetis Inc. reported a slight increase in revenue for the third quarter of 2025, reaching $2.4 billion, up from $2.388 billion in the same period last year. For the nine months ending September 30, 2025, the company generated $7.08 billion in revenue, a 2% increase from $6.939 billion in 2024. The growth was attributed to a 4% price increase across its product lines, although this was partially offset by a 4% volume decrease due to the divestiture of its medicated feed additive product portfolio. Net income attributable to Zoetis increased by 6% to $721 million for the third quarter, and by 9% to $2.07 billion for the nine-month period.

In terms of operational performance, the company saw a 1% increase in revenue on a constant currency basis for the third quarter, while operational revenue for the nine months increased by 3%. The companion animal segment, which includes products for dogs and cats, showed resilience with a 3% increase in revenue, driven by strong sales of parasiticides and dermatology products. Conversely, the livestock segment experienced a decline, primarily due to the impact of the aforementioned divestiture.

Zoetis has also made strategic moves to enhance its market position. In August 2025, the company issued $1.85 billion in senior notes to refinance existing debt and support general corporate purposes. The company’s total long-term debt increased to $7.069 billion as of September 30, 2025, compared to $5.220 billion at the end of 2024. Additionally, Zoetis has continued its share repurchase program, with $4.5 billion remaining under its authorization as of the end of September 2025.

Operationally, Zoetis reported an increase in cash and cash equivalents to $2.084 billion, up from $1.987 billion at the end of 2024. The company’s accounts receivable also rose to $1.541 billion, reflecting higher sales. However, the company faced challenges with inventory levels, which increased to $2.465 billion, as it prepared for anticipated demand. The effective tax rate for the third quarter was 18.7%, down from 20.8% in the prior year, primarily due to higher discrete tax benefits.

Looking ahead, Zoetis remains focused on expanding its product portfolio and geographic reach, particularly in emerging markets. The company anticipates continued growth driven by increased pet ownership and spending on animal health products, alongside ongoing investments in research and development to innovate and meet customer needs. However, it also acknowledges potential risks from global economic conditions, foreign exchange fluctuations, and regulatory changes that could impact its operations and financial performance.